Tiered pricing of vaccines: A win-win-win situation, not a subsidy

Lancet Infectious Diseases

Volumn 5, Issue 1, 2005, Pages 58-63

  Plahte, Jens ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MERCURY; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; PRESERVATIVE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; THIOMERSAL; VACCINE;

CONSUMER; COST; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MARKET; PRIORITY JOURNAL; PROFIT; REVIEW; THEORY; VACCINE PRODUCTION;

EID: 11144250905     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)01255-1     Document Type: Note

References (36)

1. Hausdorff WP. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine. 14:1996;1179-1186
2. Barton JH. Financing of vaccines. Lancet. 355:2000;1269-1270
3. Batson A. Win-win interactions between the public and the private sectors. Nat Med. 4:1998;487-490
4. UNICEF. Supply division annual report 2000. New York/Copenhagen: United Nations Children's Fund, 2001.
5. Whitehead P, Pasternak A. Lessons learned: new procurement strategies for vaccines. Report to the GAVI Board. Boston: Mercer Management Consulting, 2002.
6. CVI. Report of the sixth meeting of the management advisory committee, London, UK, April 21-22, 1994. 1994;Children's Vaccine Initiative, London
7. Mitchell VS, Philipose NM, Sanford JP. The children's vaccine initiative: achieving the vision. 1993;National Academy Press, Washington, DC
8. Ross V. Social venture capital for neglected vaccines: creating successful alliances. The Albert B Sabin Vaccine Institute Seventh Annual Vaccine Colloquium; 2000; Cold Spring Harbor, NY.
9. Shin S, Shahi G. Vaccine production and supply in developing countries. Cutts FT, Smith PG. Vaccination and world health. 1994;37-60 John Wiley & Sons Ltd, Chichester
10. UNICEF. Supply division annual report 2001. 2002;United Nations Children's Fund, New York/Copenhagen
11. UNICEF. Supply division annual report 2002. 2003;United Nations Children's Fund, New York/Copenhagen
12. WHO. State of the world's vaccines and immunization. 2002;World Health Organization, United Nations Children's Fund, World Bank, Geneva
13. Milstien JB, Evans P, Batson A. Discussion. Cutts FT, Smith PG. Vaccination and world health. 1994;60-67 John Wiley & Sons Ltd, Chichester
14. Oversight of Immunization Costs. Subcommittee on investigations and general oversight of the committee on labor and human resources, United States Senate. 1982;US Government Printing Office, Washington, DC
15. Hackett LB, Totten JT. Report on the United States vaccine industry. 1995;Mercer Management Consulting, Commissioned by the Department of Health and Human Services, Boston
16. Clinton WJ. Public papers of the president of the United States. William J Clinton. Book I. January 20 to July 31, 1993. 1994;Office of the Federal Register, National Archives and Records Administration, Washington, DC
17. CVI. Local vaccine production: issues of quality and viability. 1999;Children's Vaccine Initiative, Geneva
18. Cohen J. Bumps on the vaccine road. Science. 265:1994;1371-1373
19. Saldarini RJ. For vaccines, the future is now. Nat Med. 4:1998;485-486
20. Lang J, Wood SC. Development of orphan vaccines: an industry perspective. Emerg Infect Dis. 5:1999;749-756
21. Whitehead P. Economic framework for global vaccine supply. Paper presented at the Children's Vaccine Initiative/Rockefeller Foundation Conference on the Global supply of New Vaccines; Bellagio; February 3-7, 1997.
22. Pauly MV, Robinson CA, Sepe SJ, et al. Supplying vaccines: an economic analysis of critical issues. 1996;IOS Press, Amsterdam
23. Brown CV. Subsidies. Deane P, Kuper J. A lexicon of economics. 1988;Routledge, London
24. Lipsey RG, Chrystal KA. An introduction to positive economics. 1995;Oxford University Press, Oxford
25. Lipsey RG, Steiner PO, Purvis DD. Economics. 1987;Harper & Row, New York
26. Stiglitz JE. Economics, 2nd ed. New York: WW Norton & Company, 1997.
27. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine. 17:1999;646-652
28. Galambos L, Sewell JE. Networks of innovation. Vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995. New York: Cambridge University Press, 1995.
29. Kremer M. Creating markets for new vaccines Part I: Rationale. http://post.economics.harvard.edu/faculty/kremer/papers/vaccine1.pdf, 2000: 1-49 (accessed Dec 3, 2004).
30. UNICEF. UNICEF says vaccine supply for children is at risk. Press release. http://www.unicef.org/newsline/02pr15capetown.htm, 2002 (accessed Dec 3, 2004).
31. Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet. 361:2003;1902-1904
32. Hinman AR. Economic aspects of vaccines and immunizations. Life Sciences - Comptes Rendus de la Academie des Sciences Series III 1999; 322: 989-94.
33. Wilde H. What are today's orphaned vaccines? Clin Infect Dis. 33:2001;648-650
34. IAVI. IAVI fact sheet. New York: The International AIDS Vaccine Initative, 2001.
35. Davis MM, Zimmerman JL, Wheeler JRC, Freed GL. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Pub Health. 92:2002;1982-1987
36. Clemens JD. Thinking downstream to accelerate the introduction of new vaccines for developing countries. Vaccine. 21:(suppl 2):2003;S114-S115